%0 Journal Article
%A Coenen, H. H.
%A Elsinga, P.H.
%A Iwata, R.
%A Kilbourn, M.R.
%A Pillai, M.R.A.
%A Rajan, M.G.R.
%A Wagner, H.N.
%A Zaknun, J.
%T Fluorine-18 radiopharmaceuticals (beyond [18F]FDG) for use in oncology and neurosciences
%J Nuclear medicine and biology
%V 37
%@ 1872-9614
%C Amsterdam [u.a.]
%I Elsevier
%M PreJuSER-7089
%P 727 - 740
%D 2010
%Z The Consultants acknowledge the IAEA for its interest and activities in this important field. The authors from the IAEA (MRAP and JJZ) thank Dr. M. Haji-Saeid, Head, Industrial Applications and Chemistry Section, Dr. M. Dondi, Head, Nuclear Medicine Section, and Dr N. Ramamoorthy, Director-NAPC, International Atomic Energy Agency for their support and encouragement.
%< Report of an IAEA Consultants Group Meeting
%X Positron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the availability of compact medical cyclotrons and automated chemistry for the production of radiopharmaceuticals. There is an armamentarium of fluorine-18 ((18)F) tracers that can be used for PET studies in the fields of oncology and neurosciences. However, most of the (18)F-tracers other than 2-deoxy-2-[18F]fluoro-D-glucose (FDG) are in less than optimum human use and there is considerable scope to bring potentially useful (18)F-tracers to clinical investigation stage. The International Atomic Energy Agency (IAEA) convened a consultants' group meeting to review the current status of (18)F-based radiotracers and to suggest means for accelerating their use for diagnostic applications. The consultants reviewed the developments including the synthetic approaches for the preparation of (18)F-tracers for oncology and neurosciences. A selection of three groups of (18)F-tracers that are useful either in oncology or in neurosciences was done based on well-defined criteria such as application, lack of toxicity, availability of precursors and ease of synthesis. Based on the recommendations of the consultants' group meeting, IAEA started a coordinated research project on "Development of (18)F radiopharmaceuticals (beyond [(18)F]FDG) for use in oncology and neurosciences" in which 14 countries are participating in a 3-year collaborative program. The outcomes of the coordinated research project are expected to catalyze the wider application of several more (18)F-radiopharmaceuticals beyond FDG for diagnostic applications in oncology and neurosciences.
%K Animals
%K Fluorodeoxyglucose F18: diagnostic use
%K Humans
%K Neoplasms: radionuclide imaging
%K Nervous System Diseases: radionuclide imaging
%K Radiopharmaceuticals: diagnostic use
%K Radiopharmaceuticals (NLM Chemicals)
%K Fluorodeoxyglucose F18 (NLM Chemicals)
%K J (WoSType)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:20870148
%U <Go to ISI:>//WOS:000282803500001
%R 10.1016/j.nucmedbio.2010.04.185
%U https://juser.fz-juelich.de/record/7089